Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Eyes Development Of Ebola Vaccine
by Michael McCoy
August 18, 2014
| A version of this story appeared in
Volume 92, Issue 33
GlaxoSmithKline says it is in discussions with regulators about beginning Phase I clinical trials of an Ebola vaccine candidate. GSK acquired the product as part of its May 2013 purchase of the Swiss vaccines firm Okairos for $325 million. The British drugmaker says it is working with NIH’s Vaccine Research Center to advance development of what is now an early-stage candidate. It cautions that clinical development for a new vaccine can take 10 or more years and that accelerating the process is difficult.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter